References
- Di Lorenzo G , PagliaroLC, BuonerbaC, DorffTB, LeeRJ, Di LorenzoG. Penile cancer: current therapy and future directions. Ann. Oncol.24(5), 1179–1189 (2013).
- Novara G , GalfanoA, De MarcoV, ArtibaniW, FicarraV. Prognostic factors in squamous cell carcinoma of the penis. Nat. Clin. Pract. Urol.4(3), 140–146 (2007).
- Djajadiningrat RS , GraaflandNM, van WerkhovenEet al. Contemporary management of regional nodes in penile cancer-improvement of survival? J. Urol. 191(1), 68–73 (2014).
- Pagliaro LC , WilliamsDL, DalianiDet al. Neoadjuvant paclitaxel, ifosamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J. Clin. Oncol.28, 3851–3857 (2010).
- Chen MF , ChenWC, WuCT, ChuangCK, NgKF, ChangJT. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J. Urol.22(1), 60–66 (2004).
- Di Lorenzo G , BuonerbaC, FedericoPet al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int.110(11 Pt B), E661–E666 (2012).
- Di Lorenzo G , FedericoP, BuonerbaC. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur. Urol.60(6), 1280–1284 (2011).
- Di Lorenzo G , BuonerbaC, FerroMet al. The epidermal growth factor receptors as biological targets in penile cancer. Expert Opin. Biol. Ther.11, 1–4 (2014).
- Stankiewicz E , ProwseDM, NgMet al. Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS ONE6(3), e17517 (2011).
- Kim HS , KwonHJ, JungI. Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. Clin. Cancer Res.21, 544 (2015).
- Kendra K , PlummerR, SalgiaRet al. A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Mol. Cancer Ther. doi:10.1158/1535-7163.MCT-14-0431 (2014) ( Epub ahead of print).
- Li D , HanZ, LiuJ, ZhangX, RenJ, YanL, LiuH, XuZ. Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67. Med. Oncol.30(4), 702 (2013).
- Aparicio LM , PulidoEG, GallegoGA. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs23(1), 1–11 (2012).
- Di Lorenzo G , BuonerbaC, KantoffPW. Immunotherapy for the treatment of prostate cancer. Nat. Rev. Clin. Oncol.8(9), 551–561 (2011).
- Stanley M . HPV vaccination in boys and men. Hum. Vaccin. Immunother.10(7), 2109–2111 (2014).
- Ward MJ , ThirdboroughSM, MellowsTet al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer Br. J. Cancer 110(2), 489–500 (2014).
- Djajadiningrat RS , HorenblasS, HeidemanDA, SandersJ, de JongJ, JordanovaES. Classic and Nonclassic HLA Class I Expression in Penile Cancer and Relation to HPV Status and Clinical Outcome. J. Urol. pii:S0022–5347(14)04903–04909 (2014) ( Epub ahead of print).
- Rosenberg SA , YangJC, SherryRMet al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res.17(13), 4550–4557 (2011).
- ClinicalTrials Database: NCT02014831. https://clinicaltrials.gov/ct2/show/NCT02014831
- ClinicalTrials Database: NCT01728233. https://clinicaltrials.gov/ct2/show/NCT01728233
- ClinicalTrials Database: NCT02279576. https://clinicaltrials.gov/ct2/show/NCT02279576
- ClinicalTrials Database: NCT02305654. https://clinicaltrials.gov/ct2/show/NCT02305654
- ClinicalTrials Database: NCT02057913. https://clinicaltrials.gov/ct2/show/NCT02057913
- ClinicalTrials Database: NCT01585428. https://clinicaltrials.gov/ct2/show/NCT01585428
- ClinicalTrials Database: NCT02280811. https://clinicaltrials.gov/ct2/show/NCT02280811